Introduction: Many cytoprotective agents have been reported to improve islet isolation and transplantation outcomes. However, several of these agents improve all cell subsets within an islet preparation; selection of non-β-cell components (eg, acinar cells) may have a negative effect on β-cell function and survival. In this study, we examined the effect of prolactin (PRL) supplementation in the culture medium to determine whether it exerted β-cell-selective cytoprotection on islet viability and function. Materials and Methods: Human islets were precultured with or without recombinant human PRL (500 μg/L) for 48 hours. The fractional viability and cellular composition of non-β-cell and β-cell-specific components were assessed using FACS and Laser Scanning Cytometry (LSC). Islet potency was assessed in vivo by transplantation into chemically induced diabetic immunodeficient mice. Results: The relative viable β-cell mass and the relative islet β-cell content in the PRL group were 28% higher (P = .018) and 19% higher (P = .029) than the control group, respectively. All transplanted mice achieved normoglycemia in both groups, indicating that PRL treatment did not alter islet function. Conclusion: PRL treatment improved β-cell-specific viability and survival of human islets in vitro. The development of novel β-cell-specific cytoprotective strategies may be of assistance in improving islet transplantation.
|Original language||English (US)|
|Number of pages||2|
|State||Published - Mar 2008|
ASJC Scopus subject areas